Polaris Partners joins the parade of new biotech funds launched in 2014 with a USD 450 million fund which exceeds the USD 400 million number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova, among others, who have launched funds of similar size in 2014. See this article in FierceBiotech.
These new funds will bring a welcome surge of new private capital to innovative biotechs. How will it be deployed and will it be enough to sustain early-stage development at a time when drug development costs are soaring? Our Wednesday plenary panel at Biotech Showcase™ will discuss these topics and others as they contemplate the next five years of private investment in the biopharmaceutical industry.
Original post on LinkedIn.